Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
Open Access
- 1 January 2017
- journal article
- Published by Korean Ophthalmological Society in Korean Journal of Ophthalmology
- Vol. 31 (5) , 424-430
Abstract
Ozkaya A, et al. Korean J Ophthalmol. 2017 Oct;31(5):424-430. https://doi.org/10.3341/kjo.2016.0125Keywords
This publication has 21 references indexed in Scilit:
- Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?Journal of Ophthalmology, 2013
- Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZONOphthalmology, 2013
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular DegenerationKorean Journal of Ophthalmology, 2011
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- EFFECTS OF VERTEPORFIN THERAPY ON CONTRAST SENSITIVITYRetina, 2002
- Second eye involvement in age-related macular degeneration: A four-year prospective studyEye, 1990
- Occult Subretinal New Vessels in Age-related Macular DegenerationOphthalmology, 1990